In vivo tau PET imaging in our clinical groups revealed increased tau tracer binding with topographical patterns resembling the distributions of tau pathology in neurodegenerative disorders such as AD and CTE [29–32]. This evidence concerns the gene MAPT and Alzheimer disease.